In the Phase 2 trial published in the New England Journal of Medicine in 2023, participants on the highest dose of 12mg reported significant reductions in appetite and food intake within the first two weeks
In addition, switching from dulaglutide therapy to injectable semaglutide therapy has a weaker BW-reducing effect than switching from other GLP-1RAs [41]
The most common side effects are gastrointestinal, including nausea, vomiting, diarrhoea, and abdominal discomfort, affecting more than 1 in 10 patients
Clinical trial data demonstrates that both agents can achieve substantial weight loss, with Retatrutide achieving up to 24% body weight reduction and Cagrilintide reaching over 20% when combined with semaglutide
Discover how these priorities create opportunities for evidence-based nutritional solutions, from cellular energy formulations to clinical longevity innovations that address consumer needs
If youre considered overweight and struggle with losing weight through traditional methods, then you may want to consider one of these two treatments